Table S4.
GO analysis of genes differentially expressed in estrogen-treated K14E6/E7 mice (E6/E7+E2) stroma versus nontransgenic (WT) stroma
| GO identifier | GO description | Count* | Percentage† | P value‡ |
| Up-regulated | ||||
| Biological processes | ||||
| GO:0006954 | Inflammatory response | 20 | 11.17 | 2.16 E -11 |
| GO:0045087 | Innate immune response | 17 | 11.97 | 3.30 E -10 |
| GO:0006955 | Immune response | 16 | 11.35 | 2.47 E -09 |
| GO:0031424 | Keratinization | 9 | 32.14 | 4.60 E -09 |
| GO:0006915 | Apoptotic process | 25 | 4.96 | 1.80 E -07 |
| GO:0008152 | Metabolic process | 47 | 2.82 | 1.24 E -06 |
| GO:0019882 | Antigen processing and presentation | 7 | 26.92 | 2.12 E -06 |
| GO:0030593 | Neutrophil chemotaxis | 7 | 25.93 | 2.20 E -06 |
| GO:0071346 | Cellular response to IFN-γ | 6 | 37.50 | 2.25 E -06 |
| GO:0042832 | Defense response to protozoan | 6 | 35.29 | 2.51 E -06 |
| KEGG pathways | ||||
| KEGG:05150 | S. aureus infection | 12 | 24.00 | 3.77 E -11 |
| KEGG:04514 | Cell adhesion molecules (CAMs) | 16 | 11.19 | 5.12 E -10 |
| KEGG:05323 | Rheumatoid arthritis | 12 | 14.81 | 5.37 E -09 |
| KEGG:05140 | Leishmaniasis | 10 | 15.63 | 8.61 E -08 |
| KEGG:05152 | Tuberculosis | 14 | 8.09 | 3.06 E -07 |
| KEGG:04670 | Leukocyte transendothelial migration | 11 | 9.40 | 1.82 E -06 |
| KEGG:04380 | Osteoclast differentiation | 11 | 9.48 | 1.94 E -06 |
| KEGG:04621 | NOD-like receptor-signaling pathway | 8 | 14.29 | 3.25 E -06 |
| KEGG:04620 | Toll-like receptor-signaling pathway | 10 | 10.00 | 3.45 E -06 |
| KEGG:05160 | Hepatitis C | 11 | 8.09 | 5.92 E -06 |
| Down-regulated | ||||
| Biological processes | ||||
| GO:0030199 | Collagen fibril organization | 9 | 32.14 | 1.03 E -10 |
| GO:0007155 | Cell adhesion | 20 | 4.44 | 8.43 E -09 |
| GO:0007507 | Heart development | 12 | 7.64 | 1.70 E -07 |
| GO:0001568 | Blood vessel development | 8 | 13.56 | 9.04 E -07 |
| GO:0030335 | Positive regulation of cell migration | 10 | 8.70 | 1.06 E -06 |
| GO:0043588 | Skin development | 7 | 16.67 | 1.62 E -06 |
| GO:0071230 | Cellular response to amino acid stimulus | 9 | 8.49 | 3.99 E -06 |
| GO:0016477 | Cell migration | 9 | 7.76 | 6.37 E -06 |
| GO:0001501 | Skeletal system development | 8 | 9.76 | 6.40 E -06 |
| GO:0050680 | Negative regulation of epithelial cell proliferation | 6 | 13.33 | 3.57 E -05 |
| KEGG pathways | ||||
| KEGG:04510 | Focal adhesion | 27 | 13.57 | 8.40 E -26 |
| KEGG:04512 | ECM–receptor interaction | 20 | 23.26 | 3.81 E -24 |
| KEGG:04974 | Protein digestion and absorption | 14 | 17.95 | 3.29 E -15 |
| KEGG:05146 | Amoebiasis | 13 | 11.40 | 1.41 E -11 |
| KEGG:05200 | Pathways in cancer | 15 | 4.67 | 6.44 E -08 |
| KEGG:04270 | Vascular smooth muscle contraction | 9 | 7.83 | 1.08 E -06 |
| KEGG:04060 | Cytokine–cytokine receptor interaction | 11 | 4.51 | 8.81 E -06 |
| KEGG:05222 | Small cell lung cancer | 7 | 8.24 | 1.76 E -05 |
| KEGG:04360 | Axon guidance | 8 | 6.15 | 2.50 E -05 |
| KEGG:04350 | TGF-β–signaling pathway | 6 | 7.14 | 1.89 E -04 |
Items are listed restricted to the top 10 most significant GO terms where applicable.
*
Number of annotated genes in input gene list included in GO term.
†
Percentage of genes within GO term associated with input gene list.
‡
Corrected hypergeometric P value.